Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23308070 | 0.91 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL28984683 | 0.90 | MEN1 (0.43) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL28721648 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL8074011 | 0.82 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12085983 | 0.79 | MEN1 (0.39) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL8157989 | 0.79 | MEN1 (0.39) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL8295974 | 0.79 | MEN1 (0.39) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL8865823 | 0.79 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14672112 | 0.79 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL22142891 | 0.78 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132384-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | ITGAL, ITGA1, ITGA5 | MEN1 3171/4885KMT2A 1129/4885KDM4C 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.